Personalized medicine for patients with MDR-TB

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 852-855

  Olaru, Ioana D ^a,b,c   Lange, Christoph ^a,b,c,d,e   Heyckendorf, Jan ^a,b,c  

^a RESEARCH CENTER BORSTEL   (Germany)

^b German Center for Infection Research   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF NAMIBIA   (Namibia)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL GENOME; DRUG MONITORING; GENE MUTATION; GENE SEQUENCE; HOST PATHOGEN INTERACTION; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERSONALIZED MEDICINE; QUALITY OF LIFE; TREATMENT OUTCOME; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG MONITORING; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PRECISION MEDICINE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84964324629     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv354     Document Type: Article

References (28)

1. WHO. Global Tuberculosis Report 2014. Geneva, Switzerland, 2014. http://www.who.int/tb/publications/global_report/en/.
2. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
3. ECDC/WHO Regional Office for Europe. Tuberculosis Surveillance and Monitoring in Europe 2015. Stockholm: ECDC, 2015. http://ecdc.europa.eu/en/publications/Publications/tuberculosis-surveillance-monitoring-Europe-2015.pdf.
4. WHO. Global Tuberculosis Report 2013. Geneva, Switzerland, 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf.
5. WHO. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, Switzerland, 2014.
6. Aung KJ, Van Deun A, Declercq E et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-7.
7. Van Deun A, Maug AKJ, Salim MAH et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-92.
8. Günther G, van Leth F, Alexandru S et al. Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerg Infect Dis 2015; 21: 409-16.
9. Günther G, van Leth F, Altet N et al. Beyond multidrug-resistant tuberculosis in Europe. A TBNET study. Int J Tuberc Lung Dis 2015; in press.
10. Günther G, Gomez GB, Lange C et al. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J 2015; 45: 1081-8.
11. Heyckendorf J, Olaru ID, RuhwaldMet al. Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2014; 190: 374-83.
12. Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-15.
13. Sanchez-Padilla E, Merker M, Beckert P et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med 2015; 372: 1179-81.
14. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-40.
15. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-72.
16. Walker TM, Kohl TA, Omar SV et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015; 15: 1193-202.
17. Brown AC, Bryant JM, Einer-Jensen K et al. Rapid whole-genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples. J Clin Microbiol 2015; 53: 2230-7.
18. Pranger AD, van Altena R, Aarnoutse RE et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38: 888-94.
19. Pasipanodya JG, McIlleron H, Burger A et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464-73.
20. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74: 839-54.
21. Alffenaar JW. Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs. J Infect Dis 2012; 205: 1765-6.
22. Vu DH, Alffenaar JW, Edelbroek PM et al. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des 2011; 17: 2931-9.
23. Magis-Escurra C, Later-Nijland HM, Alffenaar JW et al. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. Int J Antimicrob Agents 2014; 44: 229-34.
24. Tattersall WH. The survival of sputum-positive consumptives; a study of 1, 192 cases in a county borough between 1914 and 1940. Tubercle 1947; 28: 107-14.
25. Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol 2015; 15: 255-63.
26. Cohen K, Grant A, Dandara C et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G.T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14: 687-95.
27. Bienvenu E, Swart M, Dandara C et al. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. Antiviral Res 2014; 102: 44-53.
28. Mahida S, Hogarth AJ, Cowan C et al. Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives. J Interv Card Electrophysiol 2013; 37: 9-19.